TMS Co., Ltd belongs to the Health Care sector. Filings by its managers are published through EDINET (Japan FSA). In the past year (18 October 2025 to 18 October 2026), 5 filings came from 2 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
For context, the typical company on the same exchange (median of 3,419 companies) published 3 filings over the same period, against 5 filings here.
There has been no open-market purchase by an insider of TMS Co., Ltd for at least a year. The median gap between a trade and its publication by EDINET (Japan FSA) is 7 days. Until a filing is published, the market cannot know about the trade.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. These figures are compiled from regulatory filings published by EDINET (Japan FSA). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended February 2025 · cache
19 of 19 declarations
株式会社ティムス is a company focused on the health and pharmaceutical sector. It is listed on the XTKS market.
Purchases our model currently ranks for the recommendations list.
All recommendations